b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">31443726</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>02</Month>\n            <Day>20</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>02</Month>\n            <Day>25</Day>\n        </DateRevised>\n        <Article PubModel="Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1745-6215</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>20</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Aug</Month>\n                        <Day>23</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Trials</Title>\n                <ISOAbbreviation>Trials</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Follow up after sample size re-estimation in a breast cancer randomized trial for disease-free survival.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>527</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-019-3632-9</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">While the clinical trials and statistical methodology literature on sample size re-estimation (SSRE) is robust, evaluation of SSRE procedures following the completion of a clinical trial has been sparsely reported. In blinded sample size re-estimation, only nuisance parameters are re-estimated, and the blinding of the current trial treatment effect is preserved. Blinded re-estimation procedures are well-accepted by regulatory agencies and funders. We review our experience of sample size re-estimation in a large international, National Institutes of Health funded clinical trial for adjuvant breast cancer treatment, and evaluate our blinded sample size re-estimation procedure for this time-to-event trial. We evaluated the SSRE procedure by examining assumptions made during the re-estimation process, estimates resulting from re-estimation, and the impact on final trial results with and without the addition of participants, following sample size re-estimation.</AbstractText>\n                <AbstractText Label="METHODS" NlmCategory="METHODS">We compared the control group failure probabilities estimated at the time of SSRE to estimates used in the original planning, to the final un-blinded control group failure probability estimates for those included in the SSRE procedure (SSRE cohort), and to the final total control group failure probability estimates. The impact of re-estimation on the final comparison between randomized treatment groups is evaluated for those in the originally planned cohort (n\xe2\x80\x89=\xe2\x80\x89340) and for the combination of those recruited in the originally planned cohort and those added after re-estimation (n\xe2\x80\x89=\xe2\x80\x89509).</AbstractText>\n                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Very little difference is observed between the originally planned cohort and all randomized patients in the control group failure probabilities over time or in the overall hazard ratio estimating treatment effect (originally planned cohort HR 1.25 (0.86, 1.79); all randomized cohort HR 1.24 95% CI (0.91, 1.68)). At the time of blinded SSRE, the estimated control group failure probabilities at 3\xe2\x80\x89years (0.24) and 5\xe2\x80\x89years (0.40) were similar to those for the SSRE cohort once un-blinded (3\xe2\x80\x89years, 0.22 (0.16, 0.30); 5\xe2\x80\x89years, 0.33 (0.26, 0.41)).</AbstractText>\n                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found that our re-estimation procedure performed reasonably well in estimating the control group failure probabilities at the time of re-estimation. Particularly for time-to-event outcomes, pre-planned blinded SSRE procedures may be the best option to aid in maintaining power.</AbstractText>\n                <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov, NCT00201851 . Registered on 9 September 2005. Retrospectively registered.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Hade</LastName>\n                    <ForeName>Erinn M</ForeName>\n                    <Initials>EM</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8977-6443</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Biomedical Informatics, Center for Biostatistics, College of Medicine, The Ohio State University, 1800 Cannon Drive, 320 Lincoln Tower, Columbus, OH, 43210, USA. hade.2@osu.edu.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Young</LastName>\n                    <ForeName>Gregory S</ForeName>\n                    <Initials>GS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Biomedical Informatics, Center for Biostatistics, College of Medicine, The Ohio State University, 1800 Cannon Drive, 320 Lincoln Tower, Columbus, OH, 43210, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Love</LastName>\n                    <ForeName>Richard R</ForeName>\n                    <Initials>RR</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Mathematics, Statistics, and Computer Science, Marquette University, Milwaukee, WI, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <DataBankList CompleteYN="Y">\n                <DataBank>\n                    <DataBankName>ClinicalTrials.gov</DataBankName>\n                    <AccessionNumberList>\n                        <AccessionNumber>NCT00201851</AccessionNumber>\n                    </AccessionNumberList>\n                </DataBank>\n            </DataBankList>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>R01CA097375</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>5P30 CA016058-35</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>UL1TR001070</GrantID>\n                    <Acronym>TR</Acronym>\n                    <Agency>NCATS NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>08</Month>\n                <Day>23</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Trials</MedlineTA>\n            <NlmUniqueID>101263253</NlmUniqueID>\n            <ISSNLinking>1745-6215</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>\n                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>\n                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>\n                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D023381" MajorTopicYN="Y">Endpoint Determination</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008408" MajorTopicYN="Y">Mastectomy</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010052" MajorTopicYN="Y">Ovariectomy</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018579" MajorTopicYN="Y">Patient Selection</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>\n                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018401" MajorTopicYN="Y">Sample Size</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Blinded sample size re-estimation</Keyword>\n            <Keyword MajorTopicYN="N">Breast cancer</Keyword>\n            <Keyword MajorTopicYN="N">Control group failure</Keyword>\n            <Keyword MajorTopicYN="N">Time to event</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>07</Month>\n                <Day>10</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>08</Month>\n                <Day>08</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>8</Month>\n                <Day>25</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>8</Month>\n                <Day>25</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>epublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31443726</ArticleId>\n            <ArticleId IdType="doi">10.1186/s13063-019-3632-9</ArticleId>\n            <ArticleId IdType="pii">10.1186/s13063-019-3632-9</ArticleId>\n            <ArticleId IdType="pmc">PMC6708130</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Cancer. 1999 Nov 15;86(10):2053-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">10570431</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Stat Med. 2001 Sep 15-30;20(17-18):2625-43</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11523073</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Natl Cancer Inst. 2002 May 1;94(9):662-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11983754</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Stat Med. 2003 Mar 30;22(6):971-93</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12627413</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Stat Med. 2004 Aug 30;23(16):2497-508</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15287080</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Stat Med. 2006 Mar 30;25(6):917-32</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16220524</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Biom J. 2006 Aug;48(4):537-55</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16972704</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2008 Jan 10;26(2):253-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18086800</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Biom J. 2009 Apr;51(2):348-57</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19358221</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Trials. 2010 Jun;7(3):219-26</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20392786</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Breast Cancer Res Treat. 2011 Apr;126(2):479-85</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21293921</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Trials. 2011 Apr;8(2):165-74</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21478328</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Stat Med. 1990 Jan-Feb;9(1-2):65-71; discussion 71-2</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">2345839</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Natl Cancer Inst. 2015 Mar 19;107(6):djv064</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25794890</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Trials. 2016 Oct;13(5):537-44</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27094488</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Trials. 2017 Dec;14(6):597-604</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28795844</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Stat Med. 1995 May 15-30;14(9-10):1039-51; discussion 1053-5</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">7569499</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Biometrics. 1994 Dec;50(4):1029-41</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">7786985</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Biometrics. 1998 Jun;54(2):696-705</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">9629649</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'